Randomized, placebo-controlled, crossover trial design. Patients were screened for eligibility. Those meeting entry criteria were randomized to one of two treatment sequences: pioglitazone then placebo or placebo then pioglitazone. Patients were assessed every four weeks. Treatment phases were separated by a four-week washout period.
Ormseth et al. Arthritis Research & Therapy 2013 15:R110 doi:10.1186/ar4290